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Table 2. The comparison of left atrial diameters and functions between
patients with and without interatrial block and P-terminal force
Interatrial block
(+) (n¼42)
Interatrial block
(-) (n¼26) P-value
Reservoir function(%) 35.56.5 46.28.9 <0.001
Conduit function (%) 15.83.5 21.25.1 <0.001
Pump function (%) 31.44.6 39.47.2 <0.001
Left atrial diameter (mm) 46.85.6 38.43.9 <0.001
P-terminal force
(+) (n¼45)
P-terminal force
(-) (n¼23)
Reservoir function(%) 37.25.9 44.86.7 <0.001
Conduit function (%) 15.93.7 20.75.2 <0.001
Pump function (%) 32.55.2 39.87.1 <0.001
Left atrial diameter (mm) 45.55.7 39.55.5 <0.001
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Background: The Apolipoprotein B (Apo B) gene mutations characterized by
elevated low density lipoprotein cholesterol levels and premature coronary artery
disease and/or myocardial infarction. The Apo B gene is located on chromosome 2.
The Apo B gene mutation is a single base substitution (G to A) at nucleotide 10708 of
the apo B gene. This mutation gives rise to the substitution of arginine for glutamine at
residue 3500 of the apo B-100 molecule, within a region containing the putative
receptor binding domain. Although various gene polymorphsims have been studied in
patients with nonvalvuler AF who have had a stroke, Apo B gene polymorphisms
have not been studied previously. We investigated relationship between R3500Q
mutation of the Apo B gene and nonvalvular AF with Ischemic Stroke.
Methods: The Apo B R3500Q gene mutation was analysed in 70 patients with
nonvalvuler AF who have had a stroke and 70 healthy individuals with no docu-
mented episode of AF matched for age, race and sex. The Apo B R3500Q gene
mutation was identiﬁed by polymerase chain reaction (PCR) method. Distribution of
the Apo B R3500Q gene alles (allel G, allel A) and genotypes (Normal (GG) geno-
type, heterozygous (GA) or homozygous (AA) mutant genotype) were determined in
study population. Demographic characteristics and risk factors for AF and stroke were
evaluated in the study groups.
Results: There was no signiﬁcant difference with respect to age and gender between
groups. There was no statistical difference in genotype distribution among the groups.
The genotype distribution in nonvalvuler AF who have had a stroke group was as
follows: normal genotype (GG) frequency was 67 (95.7%) and heterozygous mutant
genotype (GA) frequency was 3 (4.3%). The genotype distribution in control group
was as follows: normal genotype (GG) frequency was 68 (97.1%) and heterozygous
genotype (GA) frequency was 2 (2.9%). Homozygous genotype (AA) was not
detected in both groups. There was no statistically signiﬁcant difference betwen
groups in genotype distributions.
Conclusıons: Our results suggest that the Apo B R3500Q gene mutation appears not
to be associated with nonvalvular AF with ischemic stroke in Turkish population.
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Purpose: Lichen planus is a chronic, inﬂammatory, and autoimmune mucocutaneus
disease. There has been recent research emphasis on the strong association between
inﬂammation both P-wave dispersion and dyslipidemia. The differences between the
maximum and the minimum P-wave duration on electrocardiogram are deﬁned as P-
wave dispersion. Prolongation of P-wave dispersion has been demonstrated to be an
independent risk factor for the development of atrial ﬁbrillation. The aim of this the
study was to investigate P-wave dispersion in patients with lichen planus.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTMethods: Fifty-eight patients with lichen planus and 37 age and sex-matched, healthy
controls were included in this study. We obtained electrocardiographic recordings
from all participants and used them to calculate P-wave variables. We also assessed
high-sensitive C-reactive proteins that an inﬂammatory marker and the lipid levels for
each group. Results were reported as means  standard deviations and percentages.
Results: P-wave dispersionwere signiﬁcantly higher in lichen planus patients than in the
control group (39.912.9ms, versus 32.411.8ms, p¼0.005, respectively). Also, high-
sensitive C-reactive proteins (3.52.6, versus 1.71.1, p<0.001), LDL-cholesterol
(129.631.7, versus 96.833.6, p<0.001) and, triglyceride (169.293.6, versus
110.552.7, p¼0.001)levels were signiﬁcantly higher in patients with lichen planus,
compared to controls. There was a signiﬁcant, positive correlation between high-
sensitive C-reactive proteins and P-wave dispersion (r¼0.549, p<0.001) in lichen pla-
nus patients.
Conclusıons: P-wave dispersion increased on surface electrocardiographic measure-
ments in lichen planus patients. This result may be important in early detection of
subclinical cardiac involvement. Increased P-wave dispersion should be considered, in
terms of tendency to atrial ﬁbrillation, in these patients.ERS C149
